Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. more
Time Frame | CODX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.72% | -0.4% | -1.9% |
1-Month Return | -26.35% | -4.57% | -0.37% |
3-Month Return | -39.74% | -10.14% | 4.19% |
6-Month Return | -47.55% | -5.67% | 9.34% |
1-Year Return | -36.6% | 2.53% | 25.19% |
3-Year Return | -92.25% | -0.39% | 26.48% |
5-Year Return | -24.45% | 34.57% | 85.39% |
10-Year Return | -87.45% | 103.62% | 187.16% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 214.97K | 74.55M | 97.89M | 34.22M | 6.81M | [{"date":"2019-12-31","value":0.22,"profit":true},{"date":"2020-12-31","value":76.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":34.96,"profit":true},{"date":"2023-12-31","value":6.96,"profit":true}] |
Cost of Revenue | 112.43K | 16.59M | 11.57M | 5.48M | 4.18M | [{"date":"2019-12-31","value":0.68,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":69.76,"profit":true},{"date":"2022-12-31","value":33.04,"profit":true},{"date":"2023-12-31","value":25.22,"profit":true}] |
Gross Profit | 102.54K | 57.96M | 86.31M | 28.74M | 2.63M | [{"date":"2019-12-31","value":0.12,"profit":true},{"date":"2020-12-31","value":67.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":33.29,"profit":true},{"date":"2023-12-31","value":3.04,"profit":true}] |
Gross Margin | 47.70% | 77.75% | 88.18% | 83.98% | 38.57% | [{"date":"2019-12-31","value":54.1,"profit":true},{"date":"2020-12-31","value":88.17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.24,"profit":true},{"date":"2023-12-31","value":43.74,"profit":true}] |
Operating Expenses | 6.00M | 16.27M | 40.25M | 40.33M | 44.10M | [{"date":"2019-12-31","value":13.6,"profit":true},{"date":"2020-12-31","value":36.89,"profit":true},{"date":"2021-12-31","value":91.25,"profit":true},{"date":"2022-12-31","value":91.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (5.89M) | 41.69M | 46.06M | (11.59M) | (42.71M) | [{"date":"2019-12-31","value":-12.79,"profit":false},{"date":"2020-12-31","value":90.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-25.16,"profit":false},{"date":"2023-12-31","value":-92.71,"profit":false}] |
Total Non-Operating Income/Expense | (371.60K) | 972.64K | (383.53K) | 8.84M | 5.65M | [{"date":"2019-12-31","value":-4.21,"profit":false},{"date":"2020-12-31","value":11.01,"profit":true},{"date":"2021-12-31","value":-4.34,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":63.89,"profit":true}] |
Pre-Tax Income | (6.20M) | 42.57M | 45.64M | (18.85M) | (38.11M) | [{"date":"2019-12-31","value":-13.58,"profit":false},{"date":"2020-12-31","value":93.28,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-41.3,"profit":false},{"date":"2023-12-31","value":-83.51,"profit":false}] |
Income Taxes | (126.44K) | 90.54K | 8.98M | (4.61M) | (2.78M) | [{"date":"2019-12-31","value":-1.41,"profit":false},{"date":"2020-12-31","value":1.01,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-51.34,"profit":false},{"date":"2023-12-31","value":-30.94,"profit":false}] |
Income After Taxes | (6.07M) | 42.48M | 36.66M | (14.24M) | (35.33M) | [{"date":"2019-12-31","value":-14.29,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":86.3,"profit":true},{"date":"2022-12-31","value":-33.52,"profit":false},{"date":"2023-12-31","value":-83.18,"profit":false}] |
Income From Continuous Operations | (6.20M) | 42.48M | 36.66M | (14.24M) | (42.56M) | [{"date":"2019-12-31","value":-14.59,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":86.3,"profit":true},{"date":"2022-12-31","value":-33.52,"profit":false},{"date":"2023-12-31","value":-100.2,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (6.07M) | 42.48M | 36.66M | (14.24M) | (35.33M) | [{"date":"2019-12-31","value":-14.29,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":86.3,"profit":true},{"date":"2022-12-31","value":-33.52,"profit":false},{"date":"2023-12-31","value":-83.18,"profit":false}] |
EPS (Diluted) | (0.36) | 1.36 | 1.22 | (0.46) | (1.21) | [{"date":"2019-12-31","value":-26.47,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":89.71,"profit":true},{"date":"2022-12-31","value":-33.82,"profit":false},{"date":"2023-12-31","value":-88.97,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CODX | |
---|---|
Cash Ratio | 6.50 |
Current Ratio | 6.92 |
Quick Ratio | 6.70 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CODX | |
---|---|
ROA (LTM) | -27.61% |
ROE (LTM) | -50.57% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CODX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.12 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.88 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CODX | |
---|---|
Trailing PE | NM |
Forward PE | 16.00 |
P/S (TTM) | 3.18 |
P/B | 0.36 |
Price/FCF | NM |
EV/R | 0.06 |
EV/Ebitda | 0.52 |
PEG | NM |
Co-Diagnostics Inc (CODX) share price today is $0.756
Yes, Indians can buy shares of Co-Diagnostics Inc (CODX) on Vested. To buy Co-Diagnostics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CODX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Co-Diagnostics Inc (CODX) via the Vested app. You can start investing in Co-Diagnostics Inc (CODX) with a minimum investment of $1.
You can invest in shares of Co-Diagnostics Inc (CODX) via Vested in three simple steps:
The 52-week high price of Co-Diagnostics Inc (CODX) is $2.23. The 52-week low price of Co-Diagnostics Inc (CODX) is $0.7.
The price-to-earnings (P/E) ratio of Co-Diagnostics Inc (CODX) is
The price-to-book (P/B) ratio of Co-Diagnostics Inc (CODX) is 0.36
The dividend yield of Co-Diagnostics Inc (CODX) is 0.00%
The market capitalization of Co-Diagnostics Inc (CODX) is $23.28M
The stock symbol (or ticker) of Co-Diagnostics Inc is CODX